AKTX Company Profile and Key Details

Short-term trend indicators are bullishly aligned (SMA20 7.83%, SMA50 -0.7%, SMA200 -65.85%). The stock’s 14-day RSI is 52.28 (neutral), while the ATR of 0.03 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -85.02% below its high and over 19.01% above its low. Average 10-day trading volume of 40.43 thousand shares is slightly above the 3-month average of 36.02 thousand, indicating heightened recent market interest.

Wall Street analysts project EPS growth of 46.44% annually over the next five years. Analyst sentiment is bullish. Analyst rating data shows there are 0 Strong Buy ratings, 4 Buy ratings, 0 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $27.00 to $1.00. The high target offers 621.93% upside. The low target suggests -73.26% downside. The mean target is $8.65. This offers 131.28% upside. Akari Therapeutics, Plc earnings surprise history is a consistent trend of beating forecasts. The quarter that ended April 07, 2026, missed forecasts by 66.11%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 578.72% in April 16, 2025.

Akari Therapeutics, Plc last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $5.29. This means the shares are trading below this model’s fair value.

Akari Therapeutics, Plc (NASDAQ:AKTX) closed at $3.74 USD, gaining $0.24 (6.86%) from the previous close of $3.50. The stock is currently mid-range between its 52-week high and low $3.02 and $56.80. With a market capitalization of about $3.34 million, Akari Therapeutics, Plc is classified as a micro-cap and shows lower-than-market volatility (beta ~0.65). Key stats such as the average daily volume over the past year has been around 34.90 thousand shares, in line with its 52-week average. Headquartered in London, None, Akari Therapeutics, Plc operates in the Healthcare sector and the Biotechnology industry. Led by CEO Abizer Gaslightwala, the company employs approximately 8 people and listed since January 06, 2014. Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases.

Akari Therapeutics, Plc has 1.14 million shares outstanding. The public float is 35.25 billion shares, elevated short interest at 5.14% of float. This equals 16.14 thousand shares. The short ratio is 0.26 days. Institutional investors hold 3.42% of the float. Insiders own 24.57%. Cohen Mark S holds 1.06 million shares, SABBY MANAGEMENT, LLC has 778.03 thousand shares and Huh Hoyoung has 618.66 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Akari Therapeutics, Plc trades at a P/E ratio of -0.17, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 0.11 suggesting the stock is closer to book value. The P/FCF stands at -0.3, also above market averages.

Akari Therapeutics, Plc (NASDAQ:AKTX) shares are flat -8.69% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Akari Therapeutics, Plc trading at a premium to the broader market with a P/E of -0.17. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $5.65, suggesting 51.07% upside. Our AI forecast model points to short-term weakness (-3.48% over two weeks), a medium-term fall (-60.43% over three months), and a longer-term loss (-95.19% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Akari Therapeutics, Plc stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -3.48%, with price expected at $3.61 by June 02, 2026, within a range of $2.38 to $4.77 3-Month Outlook: Projected fall of -60.43%, reaching $1.48 by August 17, 2026, with a range of $0.00 to $2.88. 1-Year Outlook: Projected loss of -95.19%, with price at $0.18 by May 19, 2027, within a range of $0.00 to $0.40.